- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S6508
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other PKM Inhibitors | PKM2 inhibitor(compound 3k) DASA-58 TEPP-46 (ML265) (±)-Shikonin TP-1454 ZIP Alkannin DL-Serine |
|
In vitro |
DMSO
: 45 mg/mL
(99.87 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 450.55 | Formula | C24H26N4O3S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1260075-17-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | AG-348 | Smiles | C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5 | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05675436 | Enrolling by invitation | Sickle Cell Anemia|Sickle Cell Thalassemia|Sickle Cell Pain|Hbss|Hbsc|Sickle Beta Thalassemia|Sickle Beta Zero Thalassemia|Sickle Cell Syndrome Variant |
National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
May 15 2024 | -- |
| NCT05935202 | Not yet recruiting | Hereditary Red Blood Cell Disorder (Disorder) |
EuroBloodNet Association |
December 21 2023 | Phase 2 |
| NCT05610657 | Completed | Moderate Hepatic Impairment |
Agios Pharmaceuticals Inc. |
January 10 2023 | Phase 1 |
| NCT05175105 | Recruiting | Pediatric Pyruvate Kinase Deficiency|Pediatric Hemolytic Anemia |
Agios Pharmaceuticals Inc. |
June 6 2022 | Phase 3 |
| NCT05144256 | Active not recruiting | Pediatric Pyruvate Kinase Deficiency|Pediatric Hemolytic Anemia |
Agios Pharmaceuticals Inc. |
June 8 2022 | Phase 3 |
| NCT05031780 | Recruiting | Sickle Cell Disease |
Agios Pharmaceuticals Inc. |
February 11 2022 | Phase 2|Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.